Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Glaxosmithkline Share News (GSK)
GSK Share
Price
GSK Share
News
GSK Share
Chat
GSK Share
Trades17,671
GSK
Live RNS
GSK Share
Charts
GSK Level 2
Console
GSK Live
Share Price
GSK Broker
Ratings
GSK Directors
Deals
GSK Financial
Diary
GSK
Fundamentals
GSK Short
Positions1
GSK
Media1
GSK Company
Research
GSK Company
Timeline2
Share Price Information for Glaxosmithkline (GSK)
Last checked at -
Last checked at 
Intraday Glaxosmithkline Share Chart
Glaxosmithkline News
GSK to pay $2.2bn to settle Zantac lawsuits
(Sharecast News) - GSK has agreed to pay $2.2bn to settle about 80,000 Zantac lawsuits in the US.
GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 bln
GSK to pay $70 million to settle whistleblower lawsuit *
TOP NEWS: GSK to settle 80,000 Zantac cases for up to USD2.2 billion
(Alliance News) - GSK PLC on Wednesday agreed to pay up to USD2.2 billion to settle the vast majority of cases linked to its heartburn medicine Zantac...
GSK trial proves RSV vaccine efficacy after three full seasons
(Alliance News) - GSK PLC on Tuesday said its Arexvy treatment was effective in treating patients suffering from a deadly respiratory virus with under...
GSK's Arexvy provides protection over three RSV seasons, trial shows
(Sharecast News) - GSK has announced positive results from a phase III trial of its Arexvy RSV vaccine, showing that just one dose of the treatment co...
GSK RSV shot 43% effective against severe disease in third year
Oct 8 (Reuters) - GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in its th...
Pfizer wins bid to invalidate GSK's patents over RSV vaccine
LONDON, Oct 7 (Reuters) - Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus ...
Pfizer wins bid to invalidate GSK's patents over RSV vaccine
LONDON, Oct 7 (Reuters) - Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus ...
Follow the stocks
